首页 > 最新文献

Current Neurology and Neuroscience Reports最新文献

英文 中文
The Glymphatic System and its Relationship to Migraine. 淋巴系统及其与偏头痛的关系。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-16 DOI: 10.1007/s11910-024-01368-5
Alana Fretes Burgos, Patricia A Olson, Angeliki Vgontzas

Purpose of review: We aim to critically review animal and human studies of the glymphatic system in migraine and propose a model for how the glymphatic system may function in migraine, based on the available evidence.

Recent findings: Early studies in animal models report migraine attacks temporarily disrupt glymphatic flow. Human imaging studies suggest chronic migraine may be associated with alterations in glymphatic system function, albeit with conflicting results. Presently, it remains unknown whether repetitive migraine attacks or frequent nights of insomnia impair glymphatic system function over time in those with migraine, and whether alterations in glymphatic function could contribute to worsening migraine disability or risk for cognitive disease. Longitudinal studies of glymphatic function in patients with migraine and insomnia, with inclusion of cognitive assessments, may be informative.

综述的目的:我们旨在批判性地回顾偏头痛中甘液系统的动物和人体研究,并根据现有证据提出一个模型,说明偏头痛中甘液系统可能如何发挥作用:早期的动物模型研究报告称,偏头痛发作时会暂时扰乱甘液流。人体成像研究表明,慢性偏头痛可能与甘回流系统功能的改变有关,但结果相互矛盾。目前,人们仍不清楚偏头痛反复发作或经常失眠是否会长期损害偏头痛患者的脑 glymphatic 系统功能,也不清楚脑 glymphatic 功能的改变是否会导致偏头痛残疾或认知疾病风险的恶化。对偏头痛和失眠患者的脑 glymphatic 功能进行纵向研究,并纳入认知评估,可能会有所启发。
{"title":"The Glymphatic System and its Relationship to Migraine.","authors":"Alana Fretes Burgos, Patricia A Olson, Angeliki Vgontzas","doi":"10.1007/s11910-024-01368-5","DOIUrl":"10.1007/s11910-024-01368-5","url":null,"abstract":"<p><strong>Purpose of review: </strong>We aim to critically review animal and human studies of the glymphatic system in migraine and propose a model for how the glymphatic system may function in migraine, based on the available evidence.</p><p><strong>Recent findings: </strong>Early studies in animal models report migraine attacks temporarily disrupt glymphatic flow. Human imaging studies suggest chronic migraine may be associated with alterations in glymphatic system function, albeit with conflicting results. Presently, it remains unknown whether repetitive migraine attacks or frequent nights of insomnia impair glymphatic system function over time in those with migraine, and whether alterations in glymphatic function could contribute to worsening migraine disability or risk for cognitive disease. Longitudinal studies of glymphatic function in patients with migraine and insomnia, with inclusion of cognitive assessments, may be informative.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyper-Acute Stroke Systems of Care and Workflow. 超急性期中风护理系统和工作流程。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-16 DOI: 10.1007/s11910-024-01367-6
Timothy J Kleinig, Patrick McMullan, Geoffrey C Cloud, Prof Christopher Bladin, Anna Ranta

Purpose of review: Recent stroke treatment advances have necessitated agile, broad-scale healthcare system redesign, to achieve optimal patient outcomes and access equity. Optimised hyperacute stroke care requires integrated pre-hospital, emergency department, stroke specialist, radiology, neurosurgical and endovascular neurointervention services, guided by a population-wide needs analysis. In this review, we survey system integration efforts, providing case studies, and identify common elements of successful initiatives.

Recent findings: Different regions and nations have evolved varied acute stroke systems depending on geography, population density and workforce. However, common facilitators to these solutions have included stroke unit care as a foundation, government-clinician synergy, pre-hospital pathway coordination, service centralisation, and stroke data guiding system improvement. Further technological advantages will minimize the geographical distance disadvantages and facilitate virtual expertise redistribution to remote areas. Continued treatment advances necessitate an integrated, adaptable, population-wide trans-disciplinary approach. A well-designed clinician-led and government-supported system can facilitate hyperacute care and scaffold future system enhancements.

回顾的目的:近期中风治疗的进展要求对医疗系统进行灵活、广泛的重新设计,以实现最佳的患者预后和公平就医。优化超急性期卒中治疗需要在全人群需求分析的指导下,整合院前、急诊科、卒中专科、放射科、神经外科和血管内神经介入服务。在这篇综述中,我们对系统整合工作进行了调查,提供了案例研究,并确定了成功举措的共同要素:不同地区和国家的急性卒中系统因地理位置、人口密度和劳动力而各不相同。然而,这些解决方案的共同促进因素包括:以卒中单元护理为基础、政府与医生协同合作、院前路径协调、服务集中化以及卒中数据指导系统改进。进一步的技术优势将最大限度地减少地理距离的劣势,促进虚拟专业技术向偏远地区的再分配。治疗技术的不断进步需要一种综合的、适应性强的、覆盖全民的跨学科方法。一个由临床医生主导、政府支持的精心设计的系统可以促进超急性期护理,并为未来的系统改进提供支架。
{"title":"Hyper-Acute Stroke Systems of Care and Workflow.","authors":"Timothy J Kleinig, Patrick McMullan, Geoffrey C Cloud, Prof Christopher Bladin, Anna Ranta","doi":"10.1007/s11910-024-01367-6","DOIUrl":"10.1007/s11910-024-01367-6","url":null,"abstract":"<p><strong>Purpose of review: </strong>Recent stroke treatment advances have necessitated agile, broad-scale healthcare system redesign, to achieve optimal patient outcomes and access equity. Optimised hyperacute stroke care requires integrated pre-hospital, emergency department, stroke specialist, radiology, neurosurgical and endovascular neurointervention services, guided by a population-wide needs analysis. In this review, we survey system integration efforts, providing case studies, and identify common elements of successful initiatives.</p><p><strong>Recent findings: </strong>Different regions and nations have evolved varied acute stroke systems depending on geography, population density and workforce. However, common facilitators to these solutions have included stroke unit care as a foundation, government-clinician synergy, pre-hospital pathway coordination, service centralisation, and stroke data guiding system improvement. Further technological advantages will minimize the geographical distance disadvantages and facilitate virtual expertise redistribution to remote areas. Continued treatment advances necessitate an integrated, adaptable, population-wide trans-disciplinary approach. A well-designed clinician-led and government-supported system can facilitate hyperacute care and scaffold future system enhancements.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in the Treatment of Pediatric Low-Grade Gliomas. 小儿低级别胶质瘤的治疗进展。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-15 DOI: 10.1007/s11910-024-01369-4
Inci Yaman Bajin, Eric Bouffet

Purpose of review: Pediatric low-grade gliomas (pLGGs) often result in significant long-term morbidities despite high overall survival rates. This review aims to consolidate the current understanding of pLGG biology and molecular features and provide an overview of current and emerging treatment strategies.

Recent findings: Surgical resection remains a primary treatment modality, supplemented by chemotherapy and radiotherapy in specific cases. However, recent advances have elucidated the molecular underpinnings of pLGGs, revealing key genetic abnormalities such as BRAF fusions and mutations and the involvement of the RAS/MAPK and mTOR pathways. Novel targeted therapies, including MEK, BRAF and pan-RAF inhibitors, have shown promise in clinical trials, demonstrating significant efficacy and manageable toxicity. Understanding of pLGGs has significantly improved, leading to more personalized treatment approaches. Targeted therapies have emerged as effective alternatives, potentially reducing long-term toxicities. Future research should focus on optimizing therapy sequences, understanding long-term impacts, and ensuring global accessibility to advanced treatments.

综述的目的:小儿低级别胶质瘤(pLGGs)尽管总体存活率高,但往往会导致严重的长期发病。本综述旨在巩固当前对 pLGG 生物学和分子特征的认识,并概述当前和新兴的治疗策略:最近的研究结果:手术切除仍是主要的治疗方式,在特定病例中辅以化疗和放疗。然而,最近的研究进展阐明了 pLGGs 的分子基础,揭示了关键的遗传异常,如 BRAF 融合和突变,以及 RAS/MAPK 和 mTOR 通路的参与。包括 MEK、BRAF 和泛 RAF 抑制剂在内的新型靶向疗法已在临床试验中显示出良好的前景,疗效显著,毒性可控。人们对 pLGGs 的认识有了显著提高,从而产生了更加个性化的治疗方法。靶向疗法已成为有效的替代疗法,有可能减少长期毒性。未来的研究应侧重于优化治疗顺序、了解长期影响并确保全球都能获得先进的治疗方法。
{"title":"Advances in the Treatment of Pediatric Low-Grade Gliomas.","authors":"Inci Yaman Bajin, Eric Bouffet","doi":"10.1007/s11910-024-01369-4","DOIUrl":"10.1007/s11910-024-01369-4","url":null,"abstract":"<p><strong>Purpose of review: </strong>Pediatric low-grade gliomas (pLGGs) often result in significant long-term morbidities despite high overall survival rates. This review aims to consolidate the current understanding of pLGG biology and molecular features and provide an overview of current and emerging treatment strategies.</p><p><strong>Recent findings: </strong>Surgical resection remains a primary treatment modality, supplemented by chemotherapy and radiotherapy in specific cases. However, recent advances have elucidated the molecular underpinnings of pLGGs, revealing key genetic abnormalities such as BRAF fusions and mutations and the involvement of the RAS/MAPK and mTOR pathways. Novel targeted therapies, including MEK, BRAF and pan-RAF inhibitors, have shown promise in clinical trials, demonstrating significant efficacy and manageable toxicity. Understanding of pLGGs has significantly improved, leading to more personalized treatment approaches. Targeted therapies have emerged as effective alternatives, potentially reducing long-term toxicities. Future research should focus on optimizing therapy sequences, understanding long-term impacts, and ensuring global accessibility to advanced treatments.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lifestyle Factors and Stroke Prevention: From the Individual to the Community. 生活方式因素与中风预防:从个人到社区。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-08-24 DOI: 10.1007/s11910-024-01370-x
Ali Saad, Laurel Cherian, Karima Benameur

Purpose of review: The overwhelming majority of stroke burden can be prevented through the pillars of lifestyle medicine: diet, exercise, sleep, substance abuse, stress management, and healthy relationships. Among these, diet confers the greatest attributable risk.

Recent findings: Despite abundant data and integration of lifestyle medicine within major stroke prevention guidelines, several barriers to effective implementation remain. These include lack of emphasis in medical education, integration in hospital certification metrics, reimbursement from medical insurance, and health policy that inadequately addresses social determinants of health. However, both top-down and bottom-up solutions introduced within the last few years are helping to break down these barriers. This review highlights recent literature and interventions that are closing the gap between the theory and practice of stroke prevention through lifestyle risk factors from a US perspective. By strategically targeting the various institutional barriers, it is possible and essential to substantially reduce stroke burden.

回顾的目的:绝大多数中风都可以通过生活方式医学的支柱来预防:饮食、运动、睡眠、药物滥用、压力管理和健康的人际关系。其中,饮食带来的可归因风险最大:尽管有丰富的数据并将生活方式医学纳入了主要的中风预防指南,但有效实施仍存在一些障碍。这些障碍包括医学教育中缺乏重视、医院认证指标中缺乏整合、医疗保险报销以及卫生政策未充分考虑健康的社会决定因素。不过,在过去几年中,自上而下和自下而上的解决方案都有助于打破这些障碍。本综述重点介绍了最近的文献和干预措施,从美国的角度来看,这些措施正在缩小通过生活方式风险因素预防中风的理论与实践之间的差距。通过战略性地针对各种体制障碍,有可能也有必要大幅降低中风负担。
{"title":"Lifestyle Factors and Stroke Prevention: From the Individual to the Community.","authors":"Ali Saad, Laurel Cherian, Karima Benameur","doi":"10.1007/s11910-024-01370-x","DOIUrl":"10.1007/s11910-024-01370-x","url":null,"abstract":"<p><strong>Purpose of review: </strong>The overwhelming majority of stroke burden can be prevented through the pillars of lifestyle medicine: diet, exercise, sleep, substance abuse, stress management, and healthy relationships. Among these, diet confers the greatest attributable risk.</p><p><strong>Recent findings: </strong>Despite abundant data and integration of lifestyle medicine within major stroke prevention guidelines, several barriers to effective implementation remain. These include lack of emphasis in medical education, integration in hospital certification metrics, reimbursement from medical insurance, and health policy that inadequately addresses social determinants of health. However, both top-down and bottom-up solutions introduced within the last few years are helping to break down these barriers. This review highlights recent literature and interventions that are closing the gap between the theory and practice of stroke prevention through lifestyle risk factors from a US perspective. By strategically targeting the various institutional barriers, it is possible and essential to substantially reduce stroke burden.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resting-State Functional MRI Approaches to Parkinsonisms and Related Dementia. 帕金森氏症及相关痴呆症的静息状态功能磁共振成像方法。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-10-01 Epub Date: 2024-07-24 DOI: 10.1007/s11910-024-01365-8
Noemi Piramide, Rosa De Micco, Mattia Siciliano, Marcello Silvestro, Alessandro Tessitore

Purpose of the review: In this review, we attempt to summarize the most updated studies that applied resting-state functional magnetic resonance imaging (rs-fMRI) in the field of Parkinsonisms and related dementia.

Recent findings: Over the past decades, increasing interest has emerged on investigating the presence and pathophysiology of cognitive symptoms in Parkinsonisms and their possible role as predictive biomarkers of neurodegenerative brain processes. In recent years, evidence has been provided, applying mainly three methodological approaches (i.e. seed-based, network-based and graph-analysis) on rs-fMRI data, with promising results. Neural correlates of cognitive impairment and dementia have been detected in patients with Parkinsonisms along the diseases course. Interestingly, early functional connectivity signatures were proposed to track and predict future progression of neurodegenerative processes. However, longitudinal studies are still sparce and further investigations are needed to overcome this knowledge gap.

综述的目的:在这篇综述中,我们试图总结在帕金森病和相关痴呆症领域应用静息态功能磁共振成像(rs-fMRI)的最新研究:过去几十年来,人们对帕金森病认知症状的存在和病理生理学及其作为脑神经退行性过程的预测性生物标志物的可能作用的研究兴趣与日俱增。近年来,主要有三种方法(即基于种子的方法、基于网络的方法和图分析方法)应用于 rs-fMRI 数据,并取得了令人鼓舞的成果。在帕金森病患者的病程中发现了认知障碍和痴呆的神经相关性。有趣的是,有人提出早期功能连接特征可用于跟踪和预测神经退行性过程的未来进展。然而,纵向研究仍然很少,需要进一步的研究来填补这一知识空白。
{"title":"Resting-State Functional MRI Approaches to Parkinsonisms and Related Dementia.","authors":"Noemi Piramide, Rosa De Micco, Mattia Siciliano, Marcello Silvestro, Alessandro Tessitore","doi":"10.1007/s11910-024-01365-8","DOIUrl":"10.1007/s11910-024-01365-8","url":null,"abstract":"<p><strong>Purpose of the review: </strong>In this review, we attempt to summarize the most updated studies that applied resting-state functional magnetic resonance imaging (rs-fMRI) in the field of Parkinsonisms and related dementia.</p><p><strong>Recent findings: </strong>Over the past decades, increasing interest has emerged on investigating the presence and pathophysiology of cognitive symptoms in Parkinsonisms and their possible role as predictive biomarkers of neurodegenerative brain processes. In recent years, evidence has been provided, applying mainly three methodological approaches (i.e. seed-based, network-based and graph-analysis) on rs-fMRI data, with promising results. Neural correlates of cognitive impairment and dementia have been detected in patients with Parkinsonisms along the diseases course. Interestingly, early functional connectivity signatures were proposed to track and predict future progression of neurodegenerative processes. However, longitudinal studies are still sparce and further investigations are needed to overcome this knowledge gap.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future. 镰状细胞性贫血青少年的中风预防和治疗:镰状细胞性贫血青少年的中风预防和治疗:当前的实践、挑战和未来的希望。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-21 DOI: 10.1007/s11910-024-01372-9
Susan Creary, Melissa G Chung, Anthony D Villella, Warren D Lo

Purpose of review: Sickle cell anemia (SCA) is an autosomal recessive inherited hemoglobinopathy that results in a high risk of stroke. SCA primarily affects an underserved minority population of children who are frequently not receiving effective, multi-disciplinary, preventative care. This article reviews primary and secondary stroke prevention and treatment for children with SCA for the general adult and pediatric neurologist, who may play an important role in providing critical neurologic evaluation and care to these children.

Recent findings: Primary stroke prevention is efficacious at reducing ischemic stroke risk, but it is not consistently implemented into clinical practice in the United States, resulting in these children remaining at high risk. Acute symptomatic stroke management requires neurology involvement and emergent transfusion to limit ischemia. Furthermore, while chronic transfusion therapy is a proven secondary preventative modality for those with prior symptomatic or silent cerebral infarcts, it carries significant burden. Newer therapies (e.g., stem cell therapies and voxelotor) deserve further study as they may hold promise in reducing stroke risk and treatment burden. Effective primary and secondary stroke prevention and treatment remain a challenge. Informing and engaging neurology providers to recognize and provide critical neurologic evaluation and treatment has potential to close care gaps.

审查目的:镰状细胞性贫血(SCA)是一种常染色体隐性遗传血红蛋白病,导致中风的风险很高。SCA 主要影响服务不足的少数群体儿童,他们往往得不到有效的多学科预防性治疗。本文为普通成人和儿科神经科医生回顾了 SCA 儿童卒中的一级和二级预防及治疗,他们可能在为这些儿童提供关键的神经评估和护理方面发挥重要作用:脑卒中一级预防可有效降低缺血性脑卒中风险,但在美国并未在临床实践中持续实施,导致这些儿童仍处于高风险状态。急性症状性中风的治疗需要神经内科的参与和紧急输血以限制缺血。此外,虽然慢性输血疗法是一种行之有效的二级预防方法,适用于既往有症状或无症状的脑梗塞患者,但它也带来了巨大的负担。较新的疗法(如干细胞疗法和体视细胞疗法)值得进一步研究,因为它们可能有望降低中风风险并减轻治疗负担。有效的脑卒中一级和二级预防与治疗仍是一项挑战。让神经科医疗人员了解并参与识别和提供关键的神经评估和治疗,有可能缩小医疗差距。
{"title":"Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future.","authors":"Susan Creary, Melissa G Chung, Anthony D Villella, Warren D Lo","doi":"10.1007/s11910-024-01372-9","DOIUrl":"https://doi.org/10.1007/s11910-024-01372-9","url":null,"abstract":"<p><strong>Purpose of review: </strong>Sickle cell anemia (SCA) is an autosomal recessive inherited hemoglobinopathy that results in a high risk of stroke. SCA primarily affects an underserved minority population of children who are frequently not receiving effective, multi-disciplinary, preventative care. This article reviews primary and secondary stroke prevention and treatment for children with SCA for the general adult and pediatric neurologist, who may play an important role in providing critical neurologic evaluation and care to these children.</p><p><strong>Recent findings: </strong>Primary stroke prevention is efficacious at reducing ischemic stroke risk, but it is not consistently implemented into clinical practice in the United States, resulting in these children remaining at high risk. Acute symptomatic stroke management requires neurology involvement and emergent transfusion to limit ischemia. Furthermore, while chronic transfusion therapy is a proven secondary preventative modality for those with prior symptomatic or silent cerebral infarcts, it carries significant burden. Newer therapies (e.g., stem cell therapies and voxelotor) deserve further study as they may hold promise in reducing stroke risk and treatment burden. Effective primary and secondary stroke prevention and treatment remain a challenge. Informing and engaging neurology providers to recognize and provide critical neurologic evaluation and treatment has potential to close care gaps.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Mutant IDH Inhibitors in the Treatment of Glioma. 突变 IDH 抑制剂在胶质瘤治疗中的作用。
IF 4.8 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-20 DOI: 10.1007/s11910-024-01378-3
Vihang Nakhate, Aleksandra B Lasica, Patrick Y Wen

Purpose of review: The identification of isocitrate dehydrogenase (IDH) mutations has led to a transformation in our understanding of gliomas and has paved the way to a new era of targeted therapy. In this article, we review the classification of IDH-mutant glioma, standard of care treatment options, clinical evidence for mutant IDH (mIDH) inhibitors, and practical implications of the recent landmark INDIGO trial.

Recent findings: In the phase 3 randomized placebo-controlled INDIGO trial, mIDH1/2 inhibitor vorasidenib increased progression-free survival among non-enhancing grade 2 IDH-mutant gliomas following surgery. This marks the first positive randomized trial of targeted therapy in IDH-mutant glioma, and led to the US Food and Drug Administration's approval of vorasidenib in August 2024 for grade 2 IDH-mutant glioma. Vorasidenib is a well-tolerated treatment that can benefit a subset of patients with IDH-mutant glioma. Targeting mIDH also remains a promising strategy for select groups of patients excluded from the INDIGO trial. Ongoing and future studies, including with new agents and with combination therapy approaches, may expand the benefit and unlock the potential of mIDH inhibitors.

综述的目的:异柠檬酸脱氢酶(IDH)突变的发现改变了我们对胶质瘤的认识,并为靶向治疗的新时代铺平了道路。本文回顾了IDH突变胶质瘤的分类、标准治疗方案、突变IDH(mIDH)抑制剂的临床证据以及最近具有里程碑意义的INDIGO试验的实际意义:在3期随机安慰剂对照INDIGO试验中,mIDH1/2抑制剂vorasidenib提高了非增强型2级IDH突变胶质瘤术后的无进展生存期。这标志着首个针对IDH突变胶质瘤的靶向治疗随机试验取得了积极成果,并促使美国食品药品管理局于2024年8月批准vorasidenib用于治疗2级IDH突变胶质瘤。Vorasidenib是一种耐受性良好的治疗方法,可使一部分IDH突变型胶质瘤患者受益。针对 mIDH 治疗也是 INDIGO 试验排除在外的特定患者群体的一种有前景的策略。正在进行的研究和未来的研究,包括使用新药和联合治疗方法的研究,可能会扩大 mIDH 抑制剂的疗效并释放其潜力。
{"title":"The Role of Mutant IDH Inhibitors in the Treatment of Glioma.","authors":"Vihang Nakhate, Aleksandra B Lasica, Patrick Y Wen","doi":"10.1007/s11910-024-01378-3","DOIUrl":"https://doi.org/10.1007/s11910-024-01378-3","url":null,"abstract":"<p><strong>Purpose of review: </strong>The identification of isocitrate dehydrogenase (IDH) mutations has led to a transformation in our understanding of gliomas and has paved the way to a new era of targeted therapy. In this article, we review the classification of IDH-mutant glioma, standard of care treatment options, clinical evidence for mutant IDH (mIDH) inhibitors, and practical implications of the recent landmark INDIGO trial.</p><p><strong>Recent findings: </strong>In the phase 3 randomized placebo-controlled INDIGO trial, mIDH1/2 inhibitor vorasidenib increased progression-free survival among non-enhancing grade 2 IDH-mutant gliomas following surgery. This marks the first positive randomized trial of targeted therapy in IDH-mutant glioma, and led to the US Food and Drug Administration's approval of vorasidenib in August 2024 for grade 2 IDH-mutant glioma. Vorasidenib is a well-tolerated treatment that can benefit a subset of patients with IDH-mutant glioma. Targeting mIDH also remains a promising strategy for select groups of patients excluded from the INDIGO trial. Ongoing and future studies, including with new agents and with combination therapy approaches, may expand the benefit and unlock the potential of mIDH inhibitors.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sleep Disturbances in Autoimmune Neurological Diseases: Mechanisms, Clinical Characteristics, Assessment, and Treatment Strategies 自身免疫性神经疾病的睡眠障碍:机制、临床特征、评估和治疗策略
IF 5.6 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-19 DOI: 10.1007/s11910-024-01377-4
Huanyu Meng, Xiaoyu Chen, Sheng Chen

Purpose of review

Sleep disturbances are a hallmark feature of various autoimmune neurological diseases (AINDs). However, limited awareness of these sleep manifestations exists among clinicians. We provide a comprehensive overview of assessment methods, characteristic sleep disturbances, the impact of specific antibodies on sleep patterns, and treatment strategies for sleep disturbances in AINDs.

Recent findings

Research advancements in sleep disturbances in autoimmune neurological disease focus primarily on four areas: mechanisms, clinical characteristics, assessment, and treatment. Regarding mechanisms, animal models for AINDs, particularly those involving specific antibodies like anti-NMDAR, anti-LGI1, and anti-IgLON5, have become more comprehensive. Recent advancements in animal models have led to the establishment of numerous models for AINDs; these models include a wide range of antibodies, including anti-NMDAR, anti-LGI1, and anti-IgLON5. Several studies using these models have revealed common mechanisms underlying sleep disturbances in these diseases. In terms of clinical characteristics, the identification of antibodies associated with recently discovered AINDs has expanded the spectrum of sleep disturbance symptoms observed compared to prior findings. A comprehensive evaluation system for the assessment of sleep disturbances has been established, including questionnaires, polysomnography, functional magnetic resonance imaging, and 18F-FDG PET/CT. Additionally, cardiopulmonary coupling shows promise as a novel assessment tool. Currently, no universally effective treatment exists for sleep disturbances in autoimmune neurological diseases, either through symptomatic treatment or immunosuppressive therapy. Further studies are needed to confirm the efficacy of new therapies and validate the benefits of existing treatments.

Summary

Sleep disturbances are a hallmark feature of AINDs. Recent advancements have significantly expanded our understanding of their assessment and treatment. However, further studies are needed to address the remaining uncertainties in sleep disturbance management.

综述目的睡眠障碍是各种自身免疫性神经疾病(AINDs)的标志性特征。然而,临床医生对这些睡眠表现的认识有限。我们对自身免疫性神经疾病的睡眠障碍评估方法、特征性睡眠障碍、特异性抗体对睡眠模式的影响以及治疗策略进行了全面概述。在机制方面,自身免疫性神经疾病的动物模型,尤其是涉及抗 NMDAR、抗 LGI1 和抗 IgLON5 等特异性抗体的动物模型,已经变得更加全面。动物模型的最新进展导致建立了许多 AINDs 模型;这些模型包括多种抗体,包括抗 NMDAR、抗 LGI1 和抗 IgLON5。利用这些模型进行的几项研究揭示了这些疾病中睡眠障碍的共同机制。在临床特征方面,与之前的研究结果相比,最近发现的AINDs相关抗体的鉴定扩大了睡眠障碍症状的范围。用于评估睡眠障碍的综合评估系统已经建立,包括问卷调查、多导睡眠图、功能磁共振成像和 18F-FDG PET/CT。此外,心肺耦合也有望成为一种新型评估工具。目前,对于自身免疫性神经疾病患者的睡眠障碍,还没有普遍有效的治疗方法,无论是对症治疗还是免疫抑制治疗。还需要进一步的研究来确认新疗法的疗效和验证现有疗法的益处。最近的研究进展极大地扩展了我们对其评估和治疗的理解。然而,我们还需要进一步的研究来解决睡眠障碍治疗中仍然存在的不确定性。
{"title":"Sleep Disturbances in Autoimmune Neurological Diseases: Mechanisms, Clinical Characteristics, Assessment, and Treatment Strategies","authors":"Huanyu Meng, Xiaoyu Chen, Sheng Chen","doi":"10.1007/s11910-024-01377-4","DOIUrl":"https://doi.org/10.1007/s11910-024-01377-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>Sleep disturbances are a hallmark feature of various autoimmune neurological diseases (AINDs). However, limited awareness of these sleep manifestations exists among clinicians. We provide a comprehensive overview of assessment methods, characteristic sleep disturbances, the impact of specific antibodies on sleep patterns, and treatment strategies for sleep disturbances in AINDs.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>Research advancements in sleep disturbances in autoimmune neurological disease focus primarily on four areas: mechanisms, clinical characteristics, assessment, and treatment. Regarding mechanisms, animal models for AINDs, particularly those involving specific antibodies like anti-NMDAR, anti-LGI1, and anti-IgLON5, have become more comprehensive. Recent advancements in animal models have led to the establishment of numerous models for AINDs; these models include a wide range of antibodies, including anti-NMDAR, anti-LGI1, and anti-IgLON5. Several studies using these models have revealed common mechanisms underlying sleep disturbances in these diseases. In terms of clinical characteristics, the identification of antibodies associated with recently discovered AINDs has expanded the spectrum of sleep disturbance symptoms observed compared to prior findings. A comprehensive evaluation system for the assessment of sleep disturbances has been established, including questionnaires, polysomnography, functional magnetic resonance imaging, and <sup>18</sup>F-FDG PET/CT. Additionally, cardiopulmonary coupling shows promise as a novel assessment tool. Currently, no universally effective treatment exists for sleep disturbances in autoimmune neurological diseases, either through symptomatic treatment or immunosuppressive therapy. Further studies are needed to confirm the efficacy of new therapies and validate the benefits of existing treatments.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Sleep disturbances are a hallmark feature of AINDs. Recent advancements have significantly expanded our understanding of their assessment and treatment. However, further studies are needed to address the remaining uncertainties in sleep disturbance management.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Population Receptive Field Sizes in Higher-Order Visual Dysfunction 群体感受野大小在高阶视觉功能障碍中的作用
IF 5.6 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-12 DOI: 10.1007/s11910-024-01375-6
Deena Elul, Netta Levin

Purpose of Review

Population receptive field (pRF) modeling is an fMRI technique used to retinotopically map visual cortex, with pRF size characterizing the degree of spatial integration. In clinical populations, most pRF mapping research has focused on damage to visual system inputs. Herein, we highlight recent work using pRF modeling to study high-level visual dysfunctions.

Recent Findings

Larger pRF sizes, indicating coarser spatial processing, were observed in homonymous visual field deficits, aging, and autism spectrum disorder. Smaller pRF sizes, indicating finer processing, were observed in Alzheimer’s disease and schizophrenia. In posterior cortical atrophy, a unique pattern was found in which pRF size changes depended on eccentricity.

Summary

Changes to pRF properties were observed in clinical populations, even in high-order impairments, explaining visual behavior. These pRF changes likely stem from altered interactions between brain regions. Furthermore, some studies suggested that pRF sizes change as part of cortical reorganization, and they can point towards future prognosis.

综述目的群体感受野(pRF)建模是一种用于视网膜视图映射视觉皮层的 fMRI 技术,pRF 的大小表征了空间整合的程度。在临床人群中,大多数 pRF 映射研究都集中在视觉系统输入的损伤上。在此,我们将重点介绍利用 pRF 建模研究高级视觉功能障碍的最新研究成果。最近的研究结果在同名视野缺损、衰老和自闭症谱系障碍中观察到的 pRF 大小较大,表明空间处理较粗略。阿尔茨海默病和精神分裂症患者的 pRF 大小较小,表明空间处理较精细。在后皮质萎缩中,发现了一种独特的模式,即 pRF 大小的变化取决于偏心率。这些 pRF 变化可能源于大脑区域之间相互作用的改变。此外,一些研究表明,pRF 大小的变化是皮质重组的一部分,它们可以为未来的预后指明方向。
{"title":"The Role of Population Receptive Field Sizes in Higher-Order Visual Dysfunction","authors":"Deena Elul, Netta Levin","doi":"10.1007/s11910-024-01375-6","DOIUrl":"https://doi.org/10.1007/s11910-024-01375-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>Population receptive field (pRF) modeling is an fMRI technique used to retinotopically map visual cortex, with pRF size characterizing the degree of spatial integration. In clinical populations, most pRF mapping research has focused on damage to visual system inputs. Herein, we highlight recent work using pRF modeling to study high-level visual dysfunctions.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>Larger pRF sizes, indicating coarser spatial processing, were observed in homonymous visual field deficits, aging, and autism spectrum disorder. Smaller pRF sizes, indicating finer processing, were observed in Alzheimer’s disease and schizophrenia. In posterior cortical atrophy, a unique pattern was found in which pRF size changes depended on eccentricity.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Changes to pRF properties were observed in clinical populations, even in high-order impairments, explaining visual behavior. These pRF changes likely stem from altered interactions between brain regions. Furthermore, some studies suggested that pRF sizes change as part of cortical reorganization, and they can point towards future prognosis.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142220820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subcortical Aphasia: An Update 皮层下失语症:最新进展
IF 5.6 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-09-11 DOI: 10.1007/s11910-024-01373-8
Victor Nascimento Almeida, Marcia Radanovic

Purpose of review

This review aims to rediscuss the leading theories concerning the role of basal ganglia and the thalamus in the genesis of aphasic symptoms in the absence of gross anatomical lesions in cortical language areas as assessed by conventional neuroimaging studies.

Recent findings

New concepts in language processing and modern neuroimaging techniques have enabled some progress in resolving the impasse between the current dominant theories: (a) direct and specific linguistic processing and (b) subcortical structures as processing relays in domain-general functions. Of particular interest are studies of connectivity based on functional magnetic resonance imaging (MRI) and tractography that highlight the impact of white matter pathway lesions on aphasia development and recovery.

Summary

Connectivity studies have put into evidence the central role of the arcuate fasciculus (AF), inferior frontal occipital fasciculus (IFOF), and uncinate fasciculus (UF) in the genesis of aphasia. Regarding the thalamus, its involvement in lexical-semantic processing through modulation of the frontal cortex is becoming increasingly apparent.

本综述旨在重新讨论有关基底节和丘脑在传统神经影像学研究评估的皮质语言区域未发生严重解剖学病变的情况下,在失语症状的形成过程中所起作用的主要理论。语言加工的新概念和现代神经影像学技术在解决目前主流理论之间的僵局方面取得了一些进展:(a) 直接和特定的语言加工和 (b) 皮层下结构作为一般领域功能的加工中继。基于功能性磁共振成像(MRI)和磁束成像(tra tractography)的连通性研究尤为引人关注,这些研究强调了白质通路病变对失语症发展和恢复的影响。至于丘脑,其通过调节额叶皮层参与词汇语义处理的作用正变得越来越明显。
{"title":"Subcortical Aphasia: An Update","authors":"Victor Nascimento Almeida, Marcia Radanovic","doi":"10.1007/s11910-024-01373-8","DOIUrl":"https://doi.org/10.1007/s11910-024-01373-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of review</h3><p>This review aims to rediscuss the leading theories concerning the role of basal ganglia and the thalamus in the genesis of aphasic symptoms in the absence of gross anatomical lesions in cortical language areas as assessed by conventional neuroimaging studies.</p><h3 data-test=\"abstract-sub-heading\">Recent findings</h3><p>New concepts in language processing and modern neuroimaging techniques have enabled some progress in resolving the impasse between the current dominant theories: (a) direct and specific linguistic processing and (b) subcortical structures as processing relays in domain-general functions. Of particular interest are studies of connectivity based on functional magnetic resonance imaging (MRI) and tractography that highlight the impact of white matter pathway lesions on aphasia development and recovery.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Connectivity studies have put into evidence the central role of the arcuate fasciculus (AF), inferior frontal occipital fasciculus (IFOF), and uncinate fasciculus (UF) in the genesis of aphasia. Regarding the thalamus, its involvement in lexical-semantic processing through modulation of the frontal cortex is becoming increasingly apparent.</p>","PeriodicalId":10831,"journal":{"name":"Current Neurology and Neuroscience Reports","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142220786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current Neurology and Neuroscience Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1